

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 00-715-B)

In the Application of:	)	
	)	
Chad A. Mirkin, et al.	)	
	)	Examiner: TBA
Serial No.: 10/716,829	)	
	)	Group Art Unit: 1656
Filed: November 18, 2003	)	
	)	Confirmation No. TBA
For: NANOPARTICLES HAVING	)	
OLIGONUCLEOTIDES ATTACHED	)	
THERETO AND USES THEREFOR	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

In order to comply with discretionary regulations 37 CFR §§1.97 and 1.98, attached hereto is Form PTO-1449, copies<sup>1</sup> of the documents listed thereon. These documents contain information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

1. Mroczkowski, et al., U.S. Patent No. 5,284,748, issued 02/08/94.
2. Engelhardt, et al., U.S. Patent No. 5,288,609, issued 02/22/94.

---

<sup>1</sup>To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the file of a parent application. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited, then none is known to undersigned.

3. Hainfield, et al., U.S. Patent No. 5,360,895, issued 11/01/94.
4. Kidwell, et al., U.S. Patent No. 5,384,265, issued 01/24/95.
5. Beebe, et al., U.S. Patent No. 5,472,881, issued 12/05/95.
6. Stimpson, et al., U.S. Patent No. 5,599,668, issued 02/04/97.
7. Kidwell, et al., U.S. Patent No. 5,637,508, issued 06/10/97.
8. Alivisatos, et al., U.S. Patent No. 5,751,018, issued 05/12/98.
9. Hansen, et al., U.S. Patent No. 5,939,021, issued 08/17/99.
10. Weiss, et al., U.S. Patent No. 5,990,479, issued 11/23/99.
11. WO 93/10564 published 27 May 1993.
12. WO 98/10289 published 12 March 1998.
13. WO 99/23258 published 14 May 1999.
14. WO 99/21934 published 06 May 1999.
15. WO 99/20789 published 29 April 1999.
16. O.D. Velez, et al., "In Situ Assembly of Collordal Particles into Miniaturized Biosensors," *Langmuir*, May 25, 1999, Vol. 15, No. 11, pp. 3693-3698 (May 25, 1999)

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Disclosure Statement is being submitted in compliance with 37 CFR 1.56 insofar as an Examiner might consider any of the cited documents important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: \_\_\_\_\_

1/14/04



Emily Miao

Registration No. 35,285

McDonnell Boehnen Hulbert & Berghoff  
300 South Wacker Drive  
Chicago, Illinois 60606  
Telephone : (312) 913-0001  
Facsimile: (312) 913-0002



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 00-715-B)

In the Application of:	)	
	)	
Chad A. Mirkin, et al.	)	
	)	Examiner: TBA
Serial No.: 10/716,829	)	
	)	Group Art Unit: 1656
Filed: November 18, 2003	)	
	)	Confirmation No. TBA
For: NANOPARTICLES HAVING	)	
OLIGONUCLEOTIDES ATTACHED	)	
THERE TO AND USES THEREFOR	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

In order to comply with discretionary regulations 37 CFR §§1.97 and 1.98, attached hereto is Form PTO-1449, copies<sup>1</sup> of the documents listed thereon. These documents contain information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

1. Natan, U.S. Patent No. 5,609,907, issued March 11, 1997.
2. Natan, U.S. Patent No. 6,025,202, issued February 15, 2000.

---

<sup>1</sup>To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the file of a parent application. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited, then none is known to undersigned.

3. Natan, et al., U.S. Patent No. 6,149,868, issued November 21, 2000.


In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Disclosure Statement is being submitted in compliance with 37 CFR 1.56 insofar as an Examiner might consider any of the cited documents important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Dated: 1/14/04

Respectfully submitted,

  
\_\_\_\_\_  
Emily Miao  
Registration No. 35,285

McDonnell Boehnen Hulbert & Berghoff  
300 South Wacker Drive  
Chicago, Illinois 60606  
Telephone : (312) 913-0001  
Facsimile: (312) 913-0002

<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b> 00-715-B	<b>Serial N .</b> 10/716,829
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)		<b>Applicant:</b> Chad A. Mirkin, et al. <b>Filing Date:</b> November 18, 2003	
		<b>Group:</b> 1656	



## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1.	5,609,907	03/11/97	Natan			
	2.	6,025,202	02/15/00	Natan			
	3.	6,149,868	11/21/00	Natan, et al.			

## FOREIGN PATENT DOCUMENTS


		Document Number	Date	Country	Class	Subclass	Translation Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).


EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-715-B	Serial No. 10/716,829
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Applicant: Chad A. Mirkin, et al.	
		Filing Date: November 18, 2003	Group: 1656



### U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class Subclass	Filing Date
	1.	5,284,748	02/22/94	Engelhardt, et al.		
	2.	5,288,609	02/08/94	Mroczkowski, et al.		
	3.	5,360,895	11/01/94	Hainfield, et al.		
	4.	5,384,265	01/24/95	Kidwell, et al.		
	5.	5,472,881	12/05/95	Beebe, et al.		
	6.	5,599,668	02/04/97	Stimpson, et al.		
	7.	5,637,508	06/10/97	Kidwell, et al.		
	8.	5,751,018	05/12/98	Alivisatos, et al.		
	9.	5,939,021	08/17/99	Hansen, et al.		
	10.	5,990,479	11/23/99	Weiss, et al.		

### FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes N
	11.	WO 93/10564	27 May 93	PCT			
	12.	WO 98/10289	12 March 98	PCT			
	13.	WO 99/23258	14 May 99	PCT			
	14.	WO 99/21934	06 May 99	PCT			
	15.	WO 99/20789	29 April 99	PCT			

### OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.

16.	O.D. Velev, et al., "In Situ Assembly of Colloidal Particles into Miniaturized Biosensors," <i>Langmuir</i> , Vol. 15, No. 11, pp. 3693-3698, May 25, 1999
-----	--

Examiner	Date Considered
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.